Literature DB >> 1401902

DRB1*0301 molecules recognize a structural motif distinct from the one recognized by most DR beta 1 alleles.

J Sidney1, C Oseroff, S Southwood, M Wall, G Ishioka, F Koning, A Sette.   

Abstract

The DR3-restricted peptide, MT 65 kDa 3-13, was used to develop a DR3-specific binding assay. The binding activity detected was strictly pH-dependent, in that it was optimal in the pH 4 to 5 range, and no activity was detected at neutral pH. By means of affinity chromatography purifications and the use of DR3-transfected fibroblasts, it was shown that no cross-reactivity exists at the level of DR52a molecules, thus allowing use of only partially purified DR3/DR52a mixtures in high throughput binding assays. The immunologic relevance of the assay established was also verified by examining the correlation between DR3 restriction and binding for a panel of DR-restricted peptides. When the structural requirements for peptide DR3 interactions were further examined by using panels of analogues of two different epitopes (Myo 132-151 and TT 830-843), it was found that DR3 molecules recognized a peptide motif distinct from the one recognized by the other major DR beta 1 alleles.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1401902

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  Naturally processed HLA-DR9/DR53 (DRB1*0901/DRB4*0101)-bound peptides.

Authors:  G Futaki; H Kobayashi; K Sato; M Taneichi; M Katagiri
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

2.  Peptide binding characteristics of the coeliac disease-associated DQ(alpha1*0501, beta1*0201) molecule.

Authors:  Y van de Wal; Y M Kooy; J W Drijfhout; R Amons; F Koning
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

3.  Selective binding of bacterial toxins to major histocompatibility complex class II-expressing cells is controlled by invariant chain and HLA-DM.

Authors:  P M Lavoie; J Thibodeau; I Cloutier; R Busch; R P Sékaly
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

4.  Measurement of MHC/peptide interactions by gel filtration or monoclonal antibody capture.

Authors:  John Sidney; Scott Southwood; Carrie Moore; Carla Oseroff; Clemencia Pinilla; Howard M Grey; Alessandro Sette
Journal:  Curr Protoc Immunol       Date:  2013-02

5.  Divergent motifs but overlapping binding repertoires of six HLA-DQ molecules frequently expressed in the worldwide human population.

Authors:  John Sidney; Amiyah Steen; Carrie Moore; Sandy Ngo; Jolan Chung; Bjoern Peters; Alessandro Sette
Journal:  J Immunol       Date:  2010-09-01       Impact factor: 5.422

6.  The role of glutamic or aspartic acid in position four of the epitope binding motif and thyrotropin receptor-extracellular domain epitope selection in Graves' disease.

Authors:  Hidefumi Inaba; William Martin; Matt Ardito; Anne Searls De Groot; Leslie J De Groot
Journal:  J Clin Endocrinol Metab       Date:  2010-04-14       Impact factor: 5.958

7.  Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes.

Authors:  Jason Greenbaum; John Sidney; Jolan Chung; Christian Brander; Bjoern Peters; Alessandro Sette
Journal:  Immunogenetics       Date:  2011-02-09       Impact factor: 2.846

8.  Identification and characterization of novel, naturally processed measles virus class II HLA-DRB1 peptides.

Authors:  Inna G Ovsyannikova; Kenneth L Johnson; David C Muddiman; Robert A Vierkant; Gregory A Poland
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

9.  Analysis of families at risk for insulin-dependent diabetes mellitus reveals that HLA antigens influence progression to clinical disease.

Authors:  M C Honeyman; L C Harrison; B Drummond; P G Colman; B D Tait
Journal:  Mol Med       Date:  1995-07       Impact factor: 6.354

10.  A structural transition in class II major histocompatibility complex proteins at mildly acidic pH.

Authors:  H A Runnels; J C Moore; P E Jensen
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.